CAR-T Meeting 2024 | The current advantages and limitations of NK-cell-based therapies
Antonio Carrasco-Yalán, MD, British American Clinic, San Isidro, Peru, briefly comments on the advantages and challenges of natural killer (NK)-cell-based therapies. This therapeutic option involves allogeneic cells, which are frozen and can be used rapidly when needed. However, many questions remain unanswered, as NK-cell therapy is still in the early stages of development. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Well, we have many advantages to using NK and CAR-NK.
First of all, it’s an allogeneic source. It means that you have ready-to-use cells in the near future that are frozen, and you can use them quite quickly for the patient in a particular situation.
The disadvantage is that, I will say that we are in an early stage of research and development, and we will require [more] proof...
Well, we have many advantages to using NK and CAR-NK.
First of all, it’s an allogeneic source. It means that you have ready-to-use cells in the near future that are frozen, and you can use them quite quickly for the patient in a particular situation.
The disadvantage is that, I will say that we are in an early stage of research and development, and we will require [more] proof. We know at least that it is safe, but we have to work on efficacy, look at the dose, look at the combination therapy, and is there any sort of maintenance.
So this R&D procedure will take some years. I think that CAR-T have many, many years on the road, and NK-cells will start.
Read more...
Disclosures
Investigator: MSD; Speaker: MSN, varifarma; Advisor: Immunovacell.
